-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BxRWaBm0iOtaLVrvktNZYhhDN+4V+N5mMQ0ar3veLAnqyCGqNrW9aEygFqyG0Je3
 Vu7cmfgKKrijcjAtDYYqEQ==

<SEC-DOCUMENT>0000902561-00-000001.txt : 20000104
<SEC-HEADER>0000902561-00-000001.hdr.sgml : 20000104
ACCESSION NUMBER:		0000902561-00-000001
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	19991221
FILED AS OF DATE:		20000103

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SUPERGEN INC
		CENTRAL INDEX KEY:			0000919722
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911841574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		
		SEC FILE NUMBER:	000-27628
		FILM NUMBER:		500480

	BUSINESS ADDRESS:	
		STREET 1:		TWO ANNABLE LANE STE 220
		CITY:			SAN RAMON
		STATE:			CA
		ZIP:			94583
		BUSINESS PHONE:		5103270200

	MAIL ADDRESS:	
		STREET 1:		TWO ANNABEL LANE STE 220
		CITY:			SAN RAMON
		STATE:			CA
		ZIP:			94583
<REPORTING-OWNER>

COMPANY DATA:	
	COMPANY CONFORMED NAME:			ABBOTT LABORATORIES
	CENTRAL INDEX KEY:			0000001800
	STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
<RELATIONSHIP>OWNER
	IRS NUMBER:				360698440
	STATE OF INCORPORATION:			IL
	FISCAL YEAR END:			1231

FILING VALUES:
	FORM TYPE:		3

BUSINESS ADDRESS:	
	STREET 1:		100 ABBOTT PARK ROAD
	STREET 2:		D-322 AP6D
	CITY:			ABBOTT PARK
	STATE:			IL
	ZIP:			60064-3500
	BUSINESS PHONE:		8479376100
</REPORTING-OWNER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<TEXT>

                                                  ------------------------------
                                                           OMB APPROVAL
                                                  ------------------------------
                                                  OMB Number
                                                  Expires:
                                                  Estimated average burden
                                                  hours per response ....... 0.5
                                                  ------------------------------

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     FORM 3

            INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
       Section 17(a) of the Public Utility Holding Company Act of 1935 or
               Section 30(f) of the Investment Company Act of 1940

________________________________________________________________________________
1.   Name and Address of Reporting Person*

     Abbott Laboratories
- --------------------------------------------------------------------------------
   (Last)                            (First)              (Middle)

    c/o Abbott Laboratories, 100 Abbott Park Road
    Dept. 322, Bldg. AP6D2
- --------------------------------------------------------------------------------
                                    (Street)

    Abbott Park                     Illinois          60064-3500
- --------------------------------------------------------------------------------
   (City)                            (State)                (Zip)

________________________________________________________________________________
2.   Date of Event Requiring Statement (Month/Day/Year)

     12/21/99
________________________________________________________________________________
3.   IRS Identification Number of Reporting Person, if an Entity (Voluntary)

       36-0698440
________________________________________________________________________________
4.   Issuer Name and Ticker or Trading Symbol

     SuperGen, Inc.  (NASDAQ:SUPG)
________________________________________________________________________________
5.   Relationship of Reporting Person to Issuer
     (Check all applicable)

     [_]  Director                             [X]  10% Owner
     [_]  Officer (give title below)           [_]  Other (specify below)


________________________________________________________________________________
6.   If Amendment, Date of Original (Month/Day/Year)


________________________________________________________________________________
7.   Individual or Joint/Group Filing  (Check applicable line)

     [X]  Form Filed by One Reporting Person

     [ ]  Form Filed by More than One Reporting Person
<PAGE>
================================================================================
             Table I -- Non-Derivative Securities Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
                                                                 3. Ownership Form:
                                      2. Amount of Securities       Direct (D) or
1. Title of Security                     Beneficially Owned         Indirect (I)       4. Nature of Indirect Beneficial Ownership
   (Instr. 4)                            (Instr. 4)                 (Instr. 5)            (Instr. 4)
- ------------------------------------------------------------------------------------------------------------------------------------
   <S>                                   <C>                         <C>                  <C>


- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock, par value $0.001           0                           D
per share
- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

====================================================================================================================================
</TABLE>

*    If the Form is filed by more than one  Reporting  Person,  see  Instruction
     5(b)(v).

Reminder: Report on a separate line for each class of securities beneficially
          owned directly or indirectly.


                                                                          (Over)
(Form 3-07/98)

<PAGE>


FORM 3 (continued)

              Table II -- Derivative Securities Beneficially Owned
         (e.g., puts, calls, warrants, options, convertible securities)

================================================================================
<TABLE>
<CAPTION>
                                                                                                        5. Owner-
                                                    3. Title and Amount of Securities                      ship
                                                       Underlying Derivative Security                      Form of
                         2. Date Exercisable           (Instr. 4)                                          Derivative
                            and Expiration Date     ---------------------------------    4. Conver-        Security:
                            (Month/Day/Year)                               Amount           sion or        Direct      6. Nature of
                         ----------------------                            or               Exercise       (D) or         Indirect
                         Date       Expira-                                Number           Price of       Indirect       Beneficial
1. Title of Derivative   Exer-      tion                                   of               Derivative     (I)            Ownership
   Security (Instr. 4)   cisable    Date            Title                  Shares           Security       (Instr. 5)     (Instr. 5)
- ------------------------------------------------------------------------------------------------------------------------------------
<S>                      <C>        <C>             <C>                    <C>           <C>            <C>            <C>


- ------------------------------------------------------------------------------------------------------------------------------------
Option                   +          3/31/03         Common Stock           +             $85/share      D
- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

====================================================================================================================================

Explanation of Responses:
+    On December 21, 1999, Abbott Laboratories was granted an option to acquire a number of shares of common stock of SuperGen, Inc.
     equal to up 49% of the then outstanding shares of common stock of SuperGen.  The option is exercisable at any time prior to
     March 31, 2003.  However, SuperGen shareholder approval is required to increase the authorized common stock of SuperGen to a
     level that would permit the full exercise of the option.
</TABLE>



       /s/ Gary P. Coughlan                                     01/03/2000
- ---------------------------------------------            -----------------------
     Senior Vice President,                                      Date
     Finance and Chief Financial Officer
     on behalf of Abbott Laboratories
      **Signature of Reporting Person


**   Intentional misstatements or omissions of facts constitute Federal Criminal
     Violations.

     See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note:  File three copies of this Form, one of which must be manually signed.
       If space provided is insufficient, see Instruction 6 for procedure.


                                                                          Page 2

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
